Price
No data yet.
Social Signal Score
Analyst Ratings
4 analystsRevenue
$169.77M+24.31%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Daniel Virnich
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Employees
- 641
- Beta
- 0.42
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 1.74
Financials
STLN has only 5 quarterly periods on file — the charts below show the full history available.
Revenue
$169.77M+24.3%Net Income
$-15.75MEBITDA
$-641.0KFree Cash Flow
$8.88MEPS (diluted)
$-0.13Shares Outstanding (diluted)
103.03M+5.7%Operating Expenses
$32.13MCash & Debt
$36.90MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $502.73M | $-60.61M | $-0.54 |
Valuation
STLNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
153+119.05%Social Signal Score
Mentions (8)
- Newsseekingalpha.com·16d ago·Positive
Starling Oncology, Inc. (STLN) Q3 2026 Earnings Call Transcript Starling Oncology, Inc. (STLN) Q3 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·16d ago·Negative
Oncology Institute Q3 Earnings Call Highlights Oncology Institute NASDAQ: STLN, referred to as Starling Oncology by executives during its earnings call, reported a second consecutive quarter of positive adjusted EBITDA as specialty pharmacy growth and stronger drug margins boosted third-quarter results.
View source ↗ - Newszacks.com·17d ago·Neutral
Starling Oncology, Inc. (STLN) Reports Q3 Loss, Beats Revenue Estimates Starling Oncology, Inc. (STLN) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.14 per share a year ago.
View source ↗ - Newsglobenewswire.com·27d ago·Neutral
Starling Oncology Announces Third Quarter 2026 Earnings Release Date and Conference Call CERRITOS, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Starling Oncology, Inc. (“STLN”) (NASDAQ: STLN) a pioneer in value-based community oncology care, today announced that the company will release its third quarter 2026 financial results on Thursday, November 5, 2026, to be followed by a conference call the same day at 5:00 p.m.
View source ↗ - Newsglobenewswire.com·52d ago·Neutral
Starling Oncology Leadership Highlights Recent and Upcoming Industry Conference Participation Physician leaders share clinical insights on value-based therapy delivery, clinical trial access and integrated behavioral health in community oncology at major industry forums Physician leaders share clinical insights on value-based therapy delivery, clinical trial access and integrated behavioral health in community oncology at major industry forums
View source ↗ - Newsseekingalpha.com·53d ago·Positive
Starling Oncology: Improving Cash Flow And Gross Profit Fuel A Re-Rating Starling Oncology is rated BUY, supported by strong secular growth and expanding adoption of its oncology managed care services. STLN's revenue model leverages scalable delegation contracts, driving higher PMPM fees, pharmacy growth, and gross profit expansion. FY26 guidance was raised: revenue is up 31%, gross profit is up 41%, and positive EBITDA ($2–$7M) and free cash flow ($10M) are expected.
View source ↗ - Newsglobenewswire.com·90d ago·Neutral
Starling Oncology to Participate in Wells Fargo Healthcare Conference CERRITOS, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Starling Oncology™, Inc. (NASDAQ: STLN), (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today announced that Dr. Daniel Virnich, Chief Executive Officer, and Rob Carter, Chief Financial Officer, will participate in the Wells Fargo Healthcare Conference, being held in Boston on Tuesday, September 8, 2026, including a f…
View source ↗ - Newsglobenewswire.com·97d ago·Neutral
… Optimize Oncology Provider Engagement and Accelerate High-Quality Care at Scale CERRITOS, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Starling Oncology™ Inc. (NASDAQ: STLN), (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today announced the launch of Starling Oncology Nexus, a proprietary technology platform built to address one of cancer care's persistent challenges: NCCN compliance by the medical community and a fragmented and administr…
View source ↗
Earnings
Thu, Mar 11(in 4 months)
Consensus estimate $-0.04 per share
Typical surprise -24.3% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$-0.13 vs $-0.05miss
- Thu, Aug 6$-0.08 vs $-0.06miss
- Thu, May 7$-0.02 vs $-0.09beat
- Thu, Mar 12$-0.06 vs $-0.09beat
- Thu, Nov 13$-0.14 vs $-0.11miss
- Wed, Aug 13$-0.15 vs $-0.12miss
Estimates and results for STLN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by STLN officers and directors.
- Bought
- $398k
- Sold
- $13.3m
8 trades
3 trades
- Chernett Joreybought
- Chernett Joreybought
- Chernett Joreybought
- Chernett Joreybought
- Chernett Joreybought
- Chernett Joreysold
- Chernett Joreybought
- Chernett Joreybought
4 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Richard Blumenthalsenate · disclosed Oct 26, 2026 (38d later)Sell$15,001 - $50,000
- Richard Blumenthalsenate · disclosed Oct 26, 2026 (33d later)Sell$1,001 - $15,000
- Richard Blumenthalsenate · disclosed Oct 26, 2026 (34d later)Sell$15,001 - $50,000
- Richard Blumenthalsenate · disclosed Oct 26, 2026 (38d later)Sell$15,001 - $50,000
- Richard Blumenthalsenate · disclosed Oct 26, 2026 (34d later)Sell$1,001 - $15,000
- Richard Blumenthalsenate · disclosed Oct 26, 2026 (38d later)Sell$1,001 - $15,000
- Richard Blumenthalsenate · disclosed Oct 26, 2026 (33d later)Sell$1,001 - $15,000
- Richard Blumenthalsenate · disclosed Oct 26, 2026 (34d later)Sell$15,001 - $50,000
- Richard Blumenthalsenate · disclosed Oct 26, 2026 (38d later)Sell$15,001 - $50,000
- Richard Blumenthalsenate · disclosed Oct 26, 2026 (34d later)Sell$1,001 - $15,000
- Richard Blumenthalsenate · disclosed Oct 26, 2026 (38d later)Sell$1,001 - $15,000
- Richard Blumenthalsenate · disclosed Oct 26, 2026 (34d later)Sell$15,001 - $50,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
